FDA Approves Frontline Sevabertinib for HER2-Mutant Advanced NSCLC Patients

The US Food and Drug Administration (FDA) has granted accelerated approval to sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals Inc.) for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations. Detected via an FDA-authorized test, this expanded regulatory decision approves the oral kinase inhibitor for frontline use in treatment-naive patients.

Sevabertinib previously received accelerated approval for patients with pretreated, locally advanced or metastatic non-squamous HER2 TKD-mutant NSCLC.

HER2 mutations represent a distinct, rare subset of non-small cell lung cancers, occurring in approximately 2% to 3% of patients. With this accelerated approval, the frontline therapeutic landscape for HER2-mutant NSCLC has expanded. Currently, 3 targeted therapies hold FDA approval for frontline administration in this biomarker-defined population: 2 oral agents and 1 intravenous antibody-drug conjugate.

Clinical Trial Efficacy and Dosing

The expanded indication was supported by efficacy data from the open-label, single-arm, multicenter, multi-cohort Phase 1/2 SOHO-01 trial (NCT05099172). Investigators evaluated HER2 TKD activating mutations in tumor tissue or plasma prior to patient enrollment. The major efficacy outcome measures were confirmed objective response rate (ORR) and duration of response (DOR), evaluated by blinded independent central review using RECIST v1.1 criteria.

In 69 patients with locally advanced or metastatic non-squamous NSCLC with HER2 TKD activating mutations who received no prior systemic therapy, sevabertinib demonstrated an ORR of 75% (95% CI: 64, 85). Among responding patients, 73% maintained a DOR of 6 months or longer, and 38% maintained a DOR of 12 months or longer. The recommended dosage is 20 mg taken orally twice daily with food until disease progression or unacceptable toxicity.

Nursing Considerations and Toxicity Management

Beth Sandy, MSN, CRNP, FAPO, an advanced practice provider at Penn Medicine's Abramson Cancer Center, explained in an interview with Oncology Nursing News that sevabertinib provides a valuable treatment option for patients. Clinicians previously administered the oral agent in second-line care, providing oncology nursing teams with established familiarity regarding its clinical profile. However, its integration into frontline practice requires structured nursing vigilance to manage treatment-associated toxicities effectively.

Gastrointestinal toxicity represents the primary management concern for nursing staff.

Key takeaways for oncology nursing teams include:

• High Diarrhea Frequency: Diarrhea occurs in 85% to 90% of patients receiving twice-daily oral sevabertinib.
• Grade 3 Toxicity Thresholds: Per the package insert, 16% of patients develop Grade 3 diarrhea, defined as an increase of 7 or more stools per day over baseline.
• Dose Hold and Reduction Protocols: Managing Grade 3 diarrhea requires holding sevabertinib administration and executing a dose reduction upon clinical resolution.
• Broader Safety Precautions: Prescribing information contains warnings for hepatotoxicity, interstitial lung disease or pneumonitis, left ventricular dysfunction, ocular toxicity, pancreatic enzyme elevation, and embryo-fetal toxicity.

Oncology nurses must counsel patients to report changes in bowel habits immediately. Initiating antidiarrheal therapy at the first loose stool and maintaining adequate oral hydration are essential nursing interventions to prevent severe dehydration, avoid hospitalizations, and maintain therapeutic continuity.

References

1. FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer. US Food and Drug Administration. September 9, 2026. Accessed September 10, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sevabertinib-locally-advanced-or-metastatic-non-squamous-non-small